Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa?
We report the development of ceftazidime-resistant strains of Pseudomonas aeruginosa in a small population of cystic fibrosis patients who had ceftazidime monotherapy over a 5-year period as clinically indicated. The background rate of less than 30% of patients with a ceftazidime-resistant strain of P. aeruginosa in their sputum each month is similar to the resistance rate to other anti-pseudomonas antibiotics that have seldom been used here. In practice this resistance has meant that for about 10% of patients each month consideration has to be given to the use of an agent other than ceftazidime.
D002442:Ceftazidime / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000150:complications*; D004352:Drug Resistance, Microbial; D005500:Follow-Up Studies; D006801:Humans; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors
D002442:Ceftazidime